Biotech China 2014
Vaccines Europe
Hotel Bloom
rue Royale 250
Brussels, Belgium
http://www.informa-ls.com/vaccines
Vaccines Europe
Informa Life Sciences 
http://www.informa-ls.com/vaccines
Hotel Bloom
rue Royale 250
Brussels
Belgium

Resources

Schedule of Presentations:

Tuesday, December 2, 2008
07:25:00 CONFERENCE 1 : VACCINE DISCOVERY AND DEVELOPMENT
07:25:00 Conference 3 : Vaccine Scale-Up and Manufacturing
07:30:00 Conference 2 : Vaccine Characterisation and Quality Control
07:30:00 Conference 2 : Registration and Morning Coffee
07:30:00 3 : Registration and Morning Coffee
07:30:00 Registration and Morning Coffee : 1
09:00:00 Chairperson’s Opening Remarks : 2 JOINT PLENARY ADDRESS
09:00:00 Chairperson’s Opening Remarks: 3 JOINT PLENARY ADDRESS
09:00:00 Chairperson’s Opening Remarks : 1 JOINT PLENARY ADDRESS
09:05:00 Vaccines today in the light of biotech / big pharma mergers and acquisitions : 2 Alexander Von Gabain
09:05:00 3 : Vaccines today in the light of biotech / big pharma mergers and acquisitions Alexander Von Gabain
09:05:00 1: Vaccines today in the light of biotech / big pharma mergers and acquisitions Alexander Von Gabain
09:50:00 3 : Current regulatory concerns regarding long-term safety of vaccines François Verdier
09:50:00 Current regulatory concerns regarding long-term safety of vaccines : 2 François Verdier
09:50:00 1: Current regulatory concerns regarding long-term safety of vaccines François Verdier
10:35:00 Morning Coffee and Poster/Exhibition Viewing Time : 2
10:35:00 3 : Morning Coffee and Poster/Exhibition Viewing Time
10:35:00 3 : EXHIBITION HALL OPENS
10:35:00 1: Morning Coffee and Poster/Exhibition Viewing Time
10:35:00 1: EXHIBITION HALL OPENS
10:35:00 EXHIBITION HALL OPENS : 2
11:15:00 1: Chairperson’s Opening Remarks
11:15:00 3 : Chairperson’s Opening Remarks
11:15:00 Chairperson’s Opening Remarks : 2
11:20:00 1: TARGET IDENTIFICATION FOR THERAPEUTIC AND PROPHYLACTIC VACCINES
11:20:00 3 : Vaccine business in developing countries – opportunities and challenges K V Balasubramaniam,
11:20:00 3 : MANUFACTURING VACCINES IN EMERGING MARKETS
11:20:00 Biophysical characterisation of vaccines : 2
11:20:00 BIOPHYSICAL ANALYSIS OF VACCINES : 2
11:20:00 1: The search for antigens and how to present and measure responses Graham Clarke,
12:00:00 2 : Advanced biophysical analysis of rPA anthrax sub-unit Allan Watkinson,
12:00:00 1: Genome mining for the identification of promising antigens Mariagrazia Pizza,
12:00:00 3 : Manufacturing vaccines in Asia and supplying to the Western world Tarit Mukhopadhyay,
12:40:00 1: SPOTLIGHT PRESENTATION
12:40:00 3 : SPOTLIGHT PRESENTATION
12:40:00 2 : SPOTLIGHT PRESENTATION
13:10:00 1: Lunch and Poster/Exhibition Viewing Time
13:10:00 3 : Lunch and Poster/Exhibition Viewing Time
13:30:00 2 : Lunch and Poster/Exhibition Viewing Time
14:10:00 1: Development of a bivalent Neisseria meningitidis serogroup B vaccine LP2086: Lisa McNeil,
14:10:00 3 : Technical and regulatory considerations in rapid scaleup of vaccine manufacturing processes Paul Jones,
14:10:00 3 : SCALE-UP STRATEGIES AND PANDEMICS
14:10:00 2 : Characterisation of adenoviral vaccines Fija Lagerwerf,
14:50:00 3 : An alternative approach to vaccine capacity scale-up James Robinson,
14:50:00 2 : Characterisation of vaccines by capillary electrophoresis: Applications and challenges Cristiana Campa,
14:50:00 1: Innovative strategies for developing vaccines for prevention and treatment Devender Sandhu,
15:30:00 2 : Afternoon Tea and Poster/Exhibition Viewing Time Join us for HIGH SPEED NETWORKING
15:30:00 1: Afternoon Tea and Poster/Exhibition Viewing Time
15:30:00 3 : Afternoon Tea and Poster/Exhibition Viewing Time Join us for HIGH SPEED NETWORKING
16:10:00 1: KEYNOTE
16:10:00 2 : Emerging analytical techniques to characterise vaccines Martha Moser,
16:10:00 2 : EMERGING TECHNOLOGIES TO CHARACTERISE VACCINES
16:10:00 1: Immunological challenges for the vaccine industry Giuseppe Del Giudice,
16:10:00 3 : Critical requirements for an effective response to influenza epidemics and pandemics Edward J. Arcuri,
16:10:00 1: DEVELOPMENT OF VACCINES WITH INCREASED IMMUNOGENICITY
16:50:00 3 : Virus-Like Particles (VLP) applications to vaccine production and gene therapy Manuel Carrondo,
16:50:00 1: Advances with adjuvants that enhance the quality of the immune response Nathalie Garcon,
16:50:00 3 : UPSTREAM PROCESSING AND ALTERNATIVE CELL LINES
16:50:00 2 : New methods to characterise proteins in aluminium adjuvant formulations Martinus Capelle,
17:30:00 2 : End of Day One followed by Drinks Reception in the Exhibition Hall
17:30:00 1: End of Day One followed by Drinks Reception in the Exhibition Hall
17:30:00 3 : End of Day One followed by Drinks Reception in the Exhibition Hall
Wednesday, December 3, 2008
08:25:00 CONFERENCE 1 : VACCINE DISCOVERY AND DEVELOPMENT
08:30:00 1: Morning Coffee
08:30:00 2 : Morning Coffee
08:30:00 3 : Morning Coffee
08:30:00 CONFERENCE 3 VACCINE SCALE-UP AND MANUFACTURING
08:30:00 CONFERENCE 2 : VACCINE CHARACTERISATION AND QUALITY CONTROL
09:00:00 2 : Chairperson’s Opening Remarks
09:00:00 1: Chairperson’s Opening Remarks
09:00:00 3 : Chairperson’s Opening Remarks
09:05:00 2 : Development and qualification/validation of biological assays Bassam Hallis,
09:05:00 1: PREDICTIVE PRE-CLINICAL STUDIES AND ANIMAL MODELS FOR GO / NO GO DECISIONS
09:05:00 1: Use of preclinical models to evaluate the immunogenicity and efficacy of ACAM-529, a vaccine candidate against genital herpes Patricia Londoño-Arcila,
09:05:00 2 : IMPROVING BIOLOGICAL ASSAYS FOR VACCINES
09:05:00 3 : Intensifying the productivity of a recombinant Ad35 manufacturing process using the PER.C6® cell substrate Alfred Luitjens,
09:05:00 3 : UPSTREAM PROCESSING AND ALTERNATIVE CELL LINES
09:45:00 1: Experiences with animal models for pre-clinical testing of therapeutic vaccines / translating animal studies into man Catherine Gérard,
09:45:00 2 : Potency tests on vaccines: Why and when Roland Dobbelaer,
09:45:00 3 : Embryonic stem cell-derived substrates for the industrial production of vaccines Stephen Brown
10:25:00 3 : Morning Coffee and Poster/Exhibition Viewing Time
10:25:00 1: Morning Coffee and Poster/Exhibition Viewing Time
10:25:00 2 : Morning Coffee and Poster/Exhibition Viewing Time
11:05:00 1: PRE-CLINICAL AND CLINICAL CASE STUDIES
11:05:00 1: Pre-clinical and clinical results with immunostimulation reconstituted influenza virosomes Rinaldo Zurbriggen,
11:05:00 3 : DOWNSTREAM PROCESSING AND PURIFICATION
11:05:00 2 : Standardisation of vaccines Genevieve Waeterloos,
11:05:00 3 : The challenge to purify live influenza virus vaccine Elisabeth Röthl,
11:45:00 3 : Bringing DNA vaccines closer to the bedside Gabriel Monteiro,
11:45:00 1: Pre-clinical and clinical experiences with adenoviral vectored vaccines for malaria, HIV and foot and mouth disease virus Douglas E. Brough,
11:45:00 2 : Production, testing and perspectives of IPV and IPV combination vaccines Michel Duchene,
12:25:00 1: SPOTLIGHT PRESENTATION
12:25:00 2 : SPOTLIGHT PRESENTATION
12:40:00 3 : SPOTLIGHT PRESENTATION
12:55:00 3 : Lunch and Poster/Exhibition Viewing Time
12:55:00 2 : Lunch and Poster/Exhibition Viewing Time
12:55:00 1: Lunch and Poster/Exhibition Viewing Time
13:35:00 3 : Production and purification of influenza virus from MDCK-cells Raf Lemmens,
13:55:00 1: Development of a novel adjuvanted flu vaccine Ronald Ellis,
13:55:00 2 : MASS SPECTROSCOPY FOR VACCINES
13:55:00 2 : Mass spectrometry as a viable tool to characterise vaccines Jan-Gunnar Gustafsson,
14:35:00 2 : Mass spectrometry reveals the antigenicity of influenza’s (winter) coat Kevin Downard,
14:35:00 3 : Optimising recombinant baculoviruses purification – an emerging vector for the new therapies Tiago Vicente,
14:35:00 1: Immunotherapy against hypertension – from vaccine design to proof-of-concept in man Patrik Maurer,
15:15:00 3 : Afternoon Tea and Poster/Exhibition Viewing Time
15:15:00 1: Afternoon Tea and Poster/Exhibition Viewing Time
15:15:00 2 : Afternoon Tea and Poster/Exhibition Viewing Time
15:45:00 3 : Scale-up in manufacturing and the development of a commercial process: The regulatory implications David Kirke,
15:45:00 2 : METHODS FOR CHARACTERISING ADJUVANTS
15:45:00 1: Correlates of protection and immune monitoring for hepatitis therapeutic vaccines Geneviève Inschauspé,
15:45:00 3 : REGULATORY CONSIDERATIONS
15:45:00 1: IMMUNE MONITORING AND CORRELATES OF PROTECTION
16:25:00 3 : Successful implementation of technology transfer
16:25:00 1: Potential correlates of protection and immune monitoring for prophylactic vaccines against chronic viral infections Danilo Casimiro,
16:25:00 2 : VACCINE DELIVERY Satyanaryana Somavarapu,
16:25:00 3 : TECHNOLOGY TRANSFER
17:05:00 3 : End of Conference
17:05:00 2 : End of Conference
17:05:00 1: End of Conference
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.